ALX Oncology (NASDAQ:ALXO) PT Lowered to $29.00 at UBS Group

ALX Oncology (NASDAQ:ALXO – Get Rating) had its target price trimmed by UBS Group from $31.00 to $29.00 in a report issued on Tuesday morning, The Fly reports.

A number of other analysts have also recently weighed in on ALXO. Credit Suisse Group lowered their price target on ALX Oncology from $38.00 to $34.00 and set an outperform rating on the stock in a research report on Friday, March 10th. HC Wainwright lowered their price target on ALX Oncology from $65.00 to $30.00 and set a buy rating on the stock in a research report on Friday, March 10th. Five research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has a consensus rating of Buy and a consensus price target of $29.83.

ALX Oncology Stock Performance

Shares of NASDAQ:ALXO opened at $5.25 on Tuesday. The business’s fifty day moving average price is $8.27 and its two-hundred day moving average price is $10.27. ALX Oncology has a fifty-two week low of $5.09 and a fifty-two week high of $20.40. The stock has a market capitalization of $214.53 million, a price-to-earnings ratio of -1.73 and a beta of 1.76. The company has a debt-to-equity ratio of 0.04, a current ratio of 9.57 and a quick ratio of 9.57.

Institutional Trading of ALX Oncology

Several large investors have recently made changes to their positions in the business. Credit Suisse AG grew its holdings in shares of ALX Oncology by 6.6% during the second quarter. Credit Suisse AG now owns 15,157 shares of the company’s stock worth $121,000 after purchasing an additional 940 shares during the last quarter. American International Group Inc. grew its holdings in shares of ALX Oncology by 14.1% during the second quarter. American International Group Inc. now owns 10,040 shares of the company’s stock worth $81,000 after purchasing an additional 1,237 shares during the last quarter. Swiss National Bank grew its holdings in shares of ALX Oncology by 8.5% during the first quarter. Swiss National Bank now owns 19,200 shares of the company’s stock worth $324,000 after purchasing an additional 1,500 shares during the last quarter. Legal & General Group Plc grew its holdings in shares of ALX Oncology by 40.6% during the second quarter. Legal & General Group Plc now owns 5,309 shares of the company’s stock worth $43,000 after purchasing an additional 1,534 shares during the last quarter. Finally, SG Americas Securities LLC grew its holdings in shares of ALX Oncology by 3.7% during the third quarter. SG Americas Securities LLC now owns 50,536 shares of the company’s stock worth $484,000 after purchasing an additional 1,815 shares during the last quarter. Institutional investors own 89.39% of the company’s stock.

About ALX Oncology

(Get Rating)

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatment of myelodysplastic syndromes; and for the treatment of acute myeloid leukemia and non-Hodgkin's lymphoma, as well as a range of solid tumor indications, including head and neck squamous cell carcinoma, human epidermal growth factor receptor 2 (HER2) positive gastric/gastroesophageal junction carcinoma, HER2-expressing breast cancer, and other solid tumors.